Gilead has gotten a new HIV preventive treatment, Yeztugo, approved, which consists of two injections a year, promising more effective prevention.
Lara Maior
Current Affairs
Foto Gilead Pharma
Always see our news on Google
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources
Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil
Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA
FDA approves first twice-yearly injection that prevents HIV infection
US approves promising preventive HIV treatment
Groundbreaking twice-a-year HIV drug that could stop transmission approved
Latest News
23:13
The Hungarian government will offer owners of eligible diesel cars 5,000 forints per month until the end of the year
22:57
Peter Magyar announces changes to Hungary’s adoption law for same-sex couples
22:38
Bucharest entered the Book of Records with “The Table That Unites.” Ciucu: “There was a big dining room today, in Constitution Square”
22:14
Anthropic’s CEO calls for slowing AI development, warning that intelligent agents could take control of the internet in the coming months
21:26
Sergey Lavrov responds to Volodymyr Zelensky: “Let him come to Moscow” for a meeting with Vladimir Putin
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
